Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes

Journal of Intravenous Nursing

Volumn 19, Issue 3, 1996, Pages 147-156

  Granger, Christopher B ^a   Miller, Julie M ^a   Bovill, Edwin G ^a   Gruber, Andras ^a   Tracy, Russell P ^a   Krucoff, Mitchell W ^a   Green, Cindy ^a   Berrios, Eric ^a   Harrington, Robert A ^a   Ohman, E Magnus ^a   Califf, Robert M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN III; FIBRINOPEPTIDE A; HEPARIN; PROTHROMBIN; THROMBIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PATIENT MONITORING; ST SEGMENT; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 9244235959     PISSN: 08965846     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Theroux P, Ouimet H, McCans J, Latour J-G, Joly P, Levy G, Pelletier E, Juneau M, Stasiak J, deGuise P, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988;319:1105-1111.
2. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336: 827-830.
3. The SCATI Group. Randomized controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. Lancet 1989;2:182-186.
4. Hirsh J. Heparin. N Engl J Med 1991;324:1565-1574.
5. Hull RD, Raskob GE, Hirsch J, Jay RM, Leclere JR, Geerts WH, Rosenbloom D. Sackett DL. Anderson C, Harrison L, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315:1109-1114.
6. Turpic AGG, Robinson JG, Doyle DJ, Mulji AS, Mishkel GJ, Sealey BJ, Cairns JA, Skingley L, Hirsh J, Gent M. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med 1989; 320:352-357.
7. Theroux P. Waters D. Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992;327:141-145.
8. Gold HK, Torres F, Garabedian H, Werner W, Jang I, Khan A, Hagstrom J, Yasuda T, Leinbach R, Newell J, et al. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 1993;21:1039-1047.
9. Mombelli G, Hof VI, Haeberli A, Straub PW. Effect of heparin on plasma fibrinopeptide A in patients with acute myocardial infarction. Circulation 1984;69:684-689.
10. Krucoff MW, Croll MA, Pope JE, Granger CB, O'Connor CM, Sigmon KN, Wagner BL, Ryan JA, Lee KL, Kerciakes DJ, et al, for the TAMI 7 Study Group. Continuous 12-lead ST-segment recovery analysis in the TAMI 7 study: performance of a noninvasive method for real-time detection of failed myocardial reperfusion. Circulation 1993;88:437-446.
11. Tracy R, Bovill E, Stump D, Lin T, Gomol T, Collen D, Mann K. Reduction of in vitro artifact during blood collection in TIMI 11. Blood 1988;72(Suppl 1):376A.
12. Gruber A, Griffin JH. Direct detection of activated protein C in blood from human subjects. Blood 1992;79:2340-2348.
13. Hofmann V, Straub PW. A radioimmunoassay for rapid measurement of human fibrinopeptide A. Thromb Res 1977;11: 171-181.
14. Nichols AB, Owen J, Grossman BA, Marcella JJ, Fleisher LN, Lee MM. Effect of heparin bonding on catheter-induced fibrin formation and platelet activation. Circulation 1984;70: 843-850.
15. Amiral J, Vissac AM, Mimilla F, Grosley B. Assay of blood activation by measurement of AT III-serine esterases complexes (ATM) using a specific monoclonal antibody 4C9. Thromb Haemost 1989;62:479(Abstract).
16. Bilezikian SB, Nossel JL, Butler VP Jr. Canfield RE, Radioimmunoassay of human fibrinopeptide B and kinetics of fibrinopeptide cleavage by different enzymes. J Clin Invest 1975;56:438-445.
17. Eisenberg PR, Sherman LA, Schectman K, Perez J, Sobel BE, Jaffe AS. Fibrinopeptide A: a marker of acute coronary thrombosis. Circulation 1985;71:912-918.
18. Bauer KA, Weitz JI. Laboratory markers of coagulation and fibrinolysis. In: Colman R, ed. Hemostasis and Thrombosis. 3rd ed. New York: Lippincott, 1994:1197-1210.
19. Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin-antithrombin complex. Blood 1982;59:1086-1097.
20. Esmon CT. The regulation of natural anticoagulant pathways. Science 1987;235:1348-1352.
21. Braunwald E, Mark DB, Jones RH, Cheitlin MD, Fuster V, McCauley KM, Edwards C, Green LA, Mushlin AI, Swain JA. Unstable Angina: Diagnosis and Management. Clinical Practice Guideline Number 10. AHCPR Publication No. 94-0602. Rockville, MD: Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, Public Health Service, U.S. Department of Health and Human Services, 1994:65.
22. Willerson JT, Casseells W. Thrombin inhibitors in unstable angina: rebound or continuation of angina after argatroban withdrawal? J Am Coll Cardiol 1993;21:1048-1051.
23. Marciniak E. Gockerman J. Heparin-induced decrease in circulating antithrombin-III. Lancet 1977;2:581-584.